Researcher Profile

Researcher Profile

Patricia McLaughlin, MS, DEd

Patricia McLaughlin, MS, DEd

Professor, Department of Neural and Behavioral Sciences
Scientific Program:Next-Generation Therapies

Research Interests

Dr. Patricia McLaughlin’s research focuses on the Opioid Growth Factor (OGF) – OGF receptor (OGFr) pathway and mechanisms of action in homeostasis and disease. Early collaborative work with Dr. Ian Zagon resulted in the identification of [Met5]-enkephalin as the endogenous ligand for the OGF-OGFr pathway. Subsequently, a new nuclear-associated receptor was identified and termed OGFr. One group in the laboratory has characterized and cloned the OGFr gene in human, mouse and rat. Protein chemistry studies, along with structural biology, determined that the OGFr is a uniquely unstructured nuclear receptor. The mechanism of action was determined to involve inhibition of DNA synthesis with the specific mechanistic pathway involving upregulation of cyclin-dependent inhibitory kinases p16 and p21. OGF action is receptor-mediated, reversible, and not associated with apoptosis/necrosis. OGF is tissue non-specific and has been identified in proliferating cells and tissues derived from all 3 dermal layers.

Currently, the lab’s work is translational, focusing on disease-based pathways that are characterized by a perturbation in the OGF-OGFr axis. Consequences of receptor blockade of the OGF-OGFr axis are being studied with an emphasis on the etiology and treatment of complications (e.g., delayed wound healing, dry eye, impaired bone composition) arising from long-term diabetes (Type 1 or Type 2). These investigations (humans and animal models) focus on treatment options and utilize confocal microscopy, animal surgery, immunohistochemistry and tissue culture.

In another series of studies, the lab is testing the hypothesis that down-regulation of the inhibitory OGF peptide plays a role in multiple sclerosis and other autoimmune diseases. The lab is also currently validating serum biomarkers and cytokine expression profiles that correspond to changes in behavior and MRI imaging that may be related to disease progression and response to therapy. The clinical and animal research is both qualitative and quantitative in design and is supported by NIH, ADA, TSF (PA) and foundations.

  • Opioid Analgesics
  • Intercellular Signaling Peptides and Proteins
  • Naltrexone
  • methionine-enkephalin receptor
  • Growth
  • Enkephalins
  • Neoplasms
  • Opioid Receptors
  • Cell Proliferation
  • Narcotic Antagonists
  • DNA
  • Brain

Recent Publications


Titunick, MB, Lewis, GS, Cain, JD, Zagon, IS & McLaughlin, PJ 2019, 'Blockade of the OGF-OGFr pathway in diabetic bone', Connective Tissue Research, vol. 60, no. 6, pp. 521-529.
McLaughlin, PJ, Sassani, JW, Titunick, MB & Zagon, IS 2019, 'Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes', BMC Ophthalmology, vol. 19, no. 1, 35.


Zagon, IS & McLaughlin, PJ 2018, 'Intermittent blockade of OGFr and treatment of autoimmune disorders', Experimental Biology and Medicine, vol. 243, no. 17-18, pp. 1323-1330.


Ludwig, MD, Zagon, IS & McLaughlin, PJ 2017, 'Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis', Brain Research Bulletin, vol. 134, pp. 1-9.
Stockdale, DP, Titunick, MB, Biegler, JM, Reed, JL, Hartung, AM, Wiemer, DF, McLaughlin, PJ & Neighbors, JD 2017, 'Selective opioid growth factor receptor antagonists based on a stilbene isostere', Bioorganic and Medicinal Chemistry, vol. 25, no. 16, pp. 4464-4474.
McLaughlin, PJ, Cain, JD, Titunick, MB, Sassani, JW & Zagon, IS 2017, 'Topical Naltrexone is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds', Advances in Wound Care, vol. 6, no. 9, pp. 279-288.


Kren, NP, Zagon, I & McLaughlin, P 2016, 'Featured Article: Nuclear export of opioid growth factor receptor is CRM1 dependent', Experimental Biology and Medicine, vol. 241, no. 3, pp. 273-281.
Hammer, LA, Waldner, H, Zagon, IS & McLaughlin, PJ 2016, 'Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis', Experimental Biology and Medicine, vol. 241, no. 1, pp. 71-78.
Liang, D, Sassani, JW, McLaughlin, PJ & Zagon, IS 2016, 'Topical Application of Naltrexone to the Ocular Surface of Healthy Volunteers: A Tolerability Study', Journal of Ocular Pharmacology and Therapeutics, vol. 32, no. 2, pp. 127-132.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)